NAD+ and precursors results: what to expect and when
NAD+ helps cells use energy; wellness injection benefits remain unproven.
Also called: NAD+, NAD, nicotinamide adenine dinucleotide, coenzyme I, DPN, NR, nicotinamide riboside, NMN, β-NMN, nicotinamide mononucleotide.
NAD+ and precursors · NAD+ coenzyme and vitamin B3-derived precursors.
A small NAD+ study used one six-hour IV infusion and measured blood and urine changes, rather than health benefits.
Evidence is separated by administered compound. NOPARK tested oral nicotinamide riboside, not injected NAD+. NAD+, NR and NMN have distinct route-specific evidence.
Key studies
- NOPARK: NR in early Parkinson disease: NR did not improve Parkinson outcomes; the main outcome favored placebo. (source)
- NAD+ infusion: six-hour pilot: A slow infusion changed blood and urine metabolites; it did not test health benefits. (source)
- NAD+ in ischemic heart failure: A small improvement in pumping function needs replication. (source)
- NAD+ added to hearing-loss care: One small add-on study reported more hearing recovery. (source)
- NAD+ versus NR infusions: NAD+ caused substantially more infusion discomfort than NR. (source)
- Single IV dose: 2024 preprint: Preliminary data suggest different infusion tolerability for NAD+ and NR. (source)
Related to NAD+ and precursors
- MOTS-c: A peptide the body makes; injection benefits and safety remain unproven.
- SS-31 (elamipretide): A peptide approved for Barth syndrome muscle strength; benefit needs confirmation and broader energy benefits remain unproven.
Sources
- GenoGenix LLC - 718739 - 01/20/2026, FDA · FDA · 2026
- Safety of beta-nicotinamide mononucleotide (β-NMN) pursuant the regulation (EU) 2015/2283 and the bioavailability of nicotinamide from this source in the context of Directive 2002/46/EC., Turck et al. · EFSA journal. European Food Safety Authority · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- 503A Categories Update for September 2024, FDA · FDA · 2025
- DailyMed - NALTREXONE HYDROCHLORIDE tablet, film coated, DailyMed · 2023
- Safety of nicotinamide riboside chloride as a novel food pursuant to Regulation (EU) 2015/2283 and bioavailability of nicotinamide from this source, in the context of Directive 2002/46/EC., Turck et al. · EFSA journal. European Food Safety Authority · 2019
- FDA reminds compounders to use ingredients suitable for sterile compounding, FDA
- FDA to Compounders: Know Your Bulks and Excipients Suppliers, FDA
- Item: /regulated-product-applications/id/application/RP-2116, Food Standards Agency
- Nicotinamide riboside chloride, Food Standards Agency
- NMN 500 (531006), Therapeutic Goods Administration
- Product information, Health Canada
- Re: Docket Number FDA-2023-P-0872, FDA
- Submitted 75-Day Premarket Notifications for New Dietary Ingredients, FDA
- TUE Physician Guidelines: Intravenous infusions and/or injections, World Anti-Doping Agency
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.